vs
Side-by-side financial comparison of ARGENX SE (ARGX) and CACI INTERNATIONAL INC (CACI). Click either name above to swap in a different company.
ARGENX SE is the larger business by last-quarter revenue ($2.5B vs $2.4B, roughly 1.1× CACI INTERNATIONAL INC). ARGENX SE runs the higher net margin — 35.5% vs 5.5%, a 29.9% gap on every dollar of revenue. On growth, ARGENX SE posted the faster year-over-year revenue change (83.2% vs 8.5%). ARGENX SE produced more free cash flow last quarter ($322.4M vs $221.4M).
AbbVie Inc. is an American pharmaceutical company headquartered in North Chicago, Illinois. They have produced drugs to treat a wide range of medical issues.
CACI International Inc is a U.S.-headquartered multinational professional services and information technology firm. It delivers custom technology solutions, cybersecurity services, data analytics, and mission-critical operational support to government defense, intelligence, civilian agencies, and select private sector clients.
ARGX vs CACI — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2026
| Metric | | |
|---|---|---|
| Revenue | $2.5B | $2.4B |
| Net Profit | $877.2M | $130.4M |
| Gross Margin | 89.5% | — |
| Operating Margin | 28.9% | 9.7% |
| Net Margin | 35.5% | 5.5% |
| Revenue YoY | 83.2% | 8.5% |
| Net Profit YoY | 1.3% | 16.6% |
| EPS (diluted) | $13.25 | $5.88 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $2.4B | ||
| Q4 25 | $2.5B | $2.2B | ||
| Q3 25 | — | $2.3B | ||
| Q2 25 | $1.8B | $2.3B | ||
| Q1 25 | — | $2.2B | ||
| Q4 24 | $1.4B | $2.1B | ||
| Q3 24 | — | $2.1B | ||
| Q2 24 | $901.9M | $2.0B |
| Q1 26 | — | $130.4M | ||
| Q4 25 | $877.2M | $123.9M | ||
| Q3 25 | — | $124.8M | ||
| Q2 25 | $414.8M | $157.9M | ||
| Q1 25 | — | $111.9M | ||
| Q4 24 | $865.6M | $109.9M | ||
| Q3 24 | — | $120.2M | ||
| Q2 24 | $-32.5M | $134.7M |
| Q1 26 | — | — | ||
| Q4 25 | 89.5% | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 89.2% | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 90.2% | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 89.4% | — |
| Q1 26 | — | 9.7% | ||
| Q4 25 | 28.9% | 9.3% | ||
| Q3 25 | — | 9.3% | ||
| Q2 25 | 19.2% | 9.0% | ||
| Q1 25 | — | 9.1% | ||
| Q4 24 | 8.7% | 8.6% | ||
| Q3 24 | — | 8.7% | ||
| Q2 24 | -15.4% | 9.7% |
| Q1 26 | — | 5.5% | ||
| Q4 25 | 35.5% | 5.6% | ||
| Q3 25 | — | 5.5% | ||
| Q2 25 | 23.4% | 6.9% | ||
| Q1 25 | — | 5.2% | ||
| Q4 24 | 64.1% | 5.2% | ||
| Q3 24 | — | 5.8% | ||
| Q2 24 | -3.6% | 6.6% |
| Q1 26 | — | $5.88 | ||
| Q4 25 | $13.25 | $5.59 | ||
| Q3 25 | — | $5.63 | ||
| Q2 25 | $6.32 | $7.11 | ||
| Q1 25 | — | $5.00 | ||
| Q4 24 | $13.33 | $4.88 | ||
| Q3 24 | — | $5.33 | ||
| Q2 24 | $-0.55 | $5.97 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $3.5B | $158.0M |
| Total DebtLower is stronger | — | $5.2B |
| Stockholders' EquityBook value | $7.3B | $4.3B |
| Total Assets | $8.7B | $11.6B |
| Debt / EquityLower = less leverage | — | 1.21× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $158.0M | ||
| Q4 25 | $3.5B | $423.0M | ||
| Q3 25 | — | $133.0M | ||
| Q2 25 | $2.1B | $106.2M | ||
| Q1 25 | — | $223.9M | ||
| Q4 24 | $1.5B | $175.7M | ||
| Q3 24 | — | $440.7M | ||
| Q2 24 | $1.4B | $134.0M |
| Q1 26 | — | $5.2B | ||
| Q4 25 | — | $3.0B | ||
| Q3 25 | — | $2.8B | ||
| Q2 25 | — | $2.9B | ||
| Q1 25 | — | $3.1B | ||
| Q4 24 | — | $3.1B | ||
| Q3 24 | — | $1.8B | ||
| Q2 24 | $11.0M | $1.5B |
| Q1 26 | — | $4.3B | ||
| Q4 25 | $7.3B | $4.1B | ||
| Q3 25 | — | $4.0B | ||
| Q2 25 | $6.1B | $3.9B | ||
| Q1 25 | — | $3.7B | ||
| Q4 24 | $5.5B | $3.7B | ||
| Q3 24 | — | $3.7B | ||
| Q2 24 | $4.3B | $3.5B |
| Q1 26 | — | $11.6B | ||
| Q4 25 | $8.7B | $8.9B | ||
| Q3 25 | — | $8.7B | ||
| Q2 25 | $7.2B | $8.6B | ||
| Q1 25 | — | $8.6B | ||
| Q4 24 | $6.2B | $8.5B | ||
| Q3 24 | — | $7.2B | ||
| Q2 24 | $4.8B | $6.8B |
| Q1 26 | — | 1.21× | ||
| Q4 25 | — | 0.72× | ||
| Q3 25 | — | 0.69× | ||
| Q2 25 | — | 0.75× | ||
| Q1 25 | — | 0.84× | ||
| Q4 24 | — | 0.82× | ||
| Q3 24 | — | 0.50× | ||
| Q2 24 | 0.00× | 0.44× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $323.3M | $508.4M |
| Free Cash FlowOCF − Capex | $322.4M | $221.4M |
| FCF MarginFCF / Revenue | 13.0% | 9.4% |
| Capex IntensityCapex / Revenue | 0.0% | 2.5% |
| Cash ConversionOCF / Net Profit | 0.37× | 3.90× |
| TTM Free Cash FlowTrailing 4 quarters | $594.5M | $641.7M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $508.4M | ||
| Q4 25 | $323.3M | $154.2M | ||
| Q3 25 | — | $171.1M | ||
| Q2 25 | $361.8M | $156.0M | ||
| Q1 25 | — | $230.3M | ||
| Q4 24 | $41.9M | $126.0M | ||
| Q3 24 | — | $34.7M | ||
| Q2 24 | $-124.7M | $157.2M |
| Q1 26 | — | $221.4M | ||
| Q4 25 | $322.4M | $138.2M | ||
| Q3 25 | — | $154.1M | ||
| Q2 25 | $356.6M | $128.0M | ||
| Q1 25 | — | $214.1M | ||
| Q4 24 | $40.9M | $116.1M | ||
| Q3 24 | — | $23.2M | ||
| Q2 24 | $-125.5M | $134.6M |
| Q1 26 | — | 9.4% | ||
| Q4 25 | 13.0% | 6.2% | ||
| Q3 25 | — | 6.7% | ||
| Q2 25 | 20.1% | 5.6% | ||
| Q1 25 | — | 9.9% | ||
| Q4 24 | 3.0% | 5.5% | ||
| Q3 24 | — | 1.1% | ||
| Q2 24 | -13.9% | 6.6% |
| Q1 26 | — | 2.5% | ||
| Q4 25 | 0.0% | 0.7% | ||
| Q3 25 | — | 0.7% | ||
| Q2 25 | 0.3% | 1.2% | ||
| Q1 25 | — | 0.7% | ||
| Q4 24 | 0.1% | 0.5% | ||
| Q3 24 | — | 0.6% | ||
| Q2 24 | 0.1% | 1.1% |
| Q1 26 | — | 3.90× | ||
| Q4 25 | 0.37× | 1.24× | ||
| Q3 25 | — | 1.37× | ||
| Q2 25 | 0.87× | 0.99× | ||
| Q1 25 | — | 2.06× | ||
| Q4 24 | 0.05× | 1.15× | ||
| Q3 24 | — | 0.29× | ||
| Q2 24 | — | 1.17× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
